Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 2
1977 2
1979 1
1980 1
1981 2
1984 4
1985 5
1987 1
1988 1
1989 4
1990 1
1991 1
1992 3
1993 5
1994 7
1995 3
1996 3
1997 7
1998 9
1999 12
2000 12
2001 7
2002 7
2003 14
2004 7
2005 8
2006 11
2007 15
2008 10
2009 10
2010 16
2011 14
2012 16
2013 21
2014 27
2015 17
2016 22
2017 20
2018 30
2019 35
2020 41
2021 41
2022 38
2023 51
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

520 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypotrichosis 12"
Page 1
Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.
Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, Tamarit ML, Galván J, Tebbs V, Massana E; Topical Finasteride Study Group. Piraccini BM, et al. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):286-294. doi: 10.1111/jdv.17738. Epub 2021 Oct 25. J Eur Acad Dermatol Venereol. 2022. PMID: 34634163 Free PMC article. Clinical Trial.
Statistically significant differences favouring topical finasteride over placebo were observed for change from baseline in TAHC at week 12 and investigator-assessed change from baseline in patient hair growth/loss at week 24. ...
Statistically significant differences favouring topical finasteride over placebo were observed for change from baseline in TAHC at we …
Pediatric Alopecia Areata.
Afford R, Leung AKC, Lam JM. Afford R, et al. Curr Pediatr Rev. 2021;17(1):45-54. doi: 10.2174/1573396316666200430084825. Curr Pediatr Rev. 2021. PMID: 32351186 Review.
Meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews were included. Only papers published in the English language were included. ...
Meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews were included. Only papers published …
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R. King B, et al. Lancet. 2023 May 6;401(10387):1518-1529. doi: 10.1016/S0140-6736(23)00222-2. Epub 2023 Apr 14. Lancet. 2023. PMID: 37062298 Clinical Trial.
Of 718 patients randomly assigned, 104 patients discontinued treatment (34 withdrew, 19 adverse events [AEs], 12 physician decision, 12 lack of efficacy, 13 lost to follow up, five rolled over to long-term study transfer, four pregnancies, two protocol deviations, o …
Of 718 patients randomly assigned, 104 patients discontinued treatment (34 withdrew, 19 adverse events [AEs], 12 physician decision, …
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, King B, Banerjee A, Banfield C, Cox LA, Dowty ME, Page K, Vincent MS, Zhang W, Zhu L, Peeva E. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2022 Apr;149(4):1318-1328. doi: 10.1016/j.jaci.2021.10.036. Epub 2021 Dec 1. J Allergy Clin Immunol. 2022. PMID: 34863853 Free article. Clinical Trial.
METHODS: Change in biomarkers in lesional scalp biopsy samples between baseline and weeks 12 and 24 was an exploratory end point, and 46 patients participated from the ritlecitinib (n = 18), brepocitinib (n = 16), and placebo (n = 12) groups. Correlations of biomark …
METHODS: Change in biomarkers in lesional scalp biopsy samples between baseline and weeks 12 and 24 was an exploratory end point, and …
European expert consensus statement on the systemic treatment of alopecia areata.
Rudnicka L, Arenbergerova M, Grimalt R, Ioannides D, Katoulis AC, Lazaridou E, Olszewska M, Ovcharenko YS, Piraccini BM, Prohic A, Rakowska A, Reygagne P, Richard MA, Soares RO, Starace M, Vañó-Galvan S, Waskiel-Burnat A. Rudnicka L, et al. J Eur Acad Dermatol Venereol. 2024 Apr;38(4):687-694. doi: 10.1111/jdv.19768. Epub 2024 Jan 2. J Eur Acad Dermatol Venereol. 2024. PMID: 38169088 Review.
The disease severity evaluation tools used in clinical practice are: the Severity of Alopecia Tool (SALT) score and the Alopecia Areata Scale (AAS). A SALT score equal to or greater than 20 constitutes a commonly accepted indication for systemic therapy in alopecia …
The disease severity evaluation tools used in clinical practice are: the Severity of Alopecia Tool (SALT) score and the Alopecia Area …
Current application of mesotherapy in pattern hair loss: A systematic review.
Tang Z, Hu Y, Wang J, Fan Z, Qu Q, Miao Y. Tang Z, et al. J Cosmet Dermatol. 2022 Oct;21(10):4184-4193. doi: 10.1111/jocd.14900. Epub 2022 Mar 14. J Cosmet Dermatol. 2022. PMID: 35253335 Review.
All literature was evaluated according to established criteria. RESULTS: We got 336 studies from searched databases, and 12 studies were included after selection process. A total of 253 males and 274 females participated in 6 randomized control trials, 2 nonrandomized cont …
All literature was evaluated according to established criteria. RESULTS: We got 336 studies from searched databases, and 12 studies w …
Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata.
King B, Mesinkovska N, Mirmirani P, Bruce S, Kempers S, Guttman-Yassky E, Roberts JL, McMichael A, Colavincenzo M, Hamilton C, Braman V, Cassella JV. King B, et al. J Am Acad Dermatol. 2022 Aug;87(2):306-313. doi: 10.1016/j.jaad.2022.03.045. Epub 2022 Mar 29. J Am Acad Dermatol. 2022. PMID: 35364216 Free article. Clinical Trial.
METHODS: In this phase 2, randomized, double-blind, placebo-controlled, sequential-design trial, patients were randomized to receive CTP-543 (4 mg, 8 mg, or 12 mg) or placebo every 12 hours for 24 weeks. RESULTS: A dose-related increase was observed in the pe …
METHODS: In this phase 2, randomized, double-blind, placebo-controlled, sequential-design trial, patients were randomized to receive CTP-543 …
Treatments for alopecia areata: a network meta-analysis.
Mateos-Haro M, Novoa-Candia M, Sánchez Vanegas G, Correa-Pérez A, Gaetano Gil A, Fernández-García S, Ortega-Quijano D, Urueña Rodriguez MG, Saceda-Corralo D, Bennouna-Dalero T, Giraldo L, Tomlinson J, Vaño-Galván S, Zamora J. Mateos-Haro M, et al. Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013719. doi: 10.1002/14651858.CD013719.pub2. Cochrane Database Syst Rev. 2023. PMID: 37870096 Review.
The primary outcomes were short-term hair regrowth 75% (between 12 and 26 weeks of follow-up), and incidence of serious adverse events. ...Considering only the prioritised interventions, 14 studies from 12 comparisons reported short-term hair regrowth 75% and 22 stu …
The primary outcomes were short-term hair regrowth 75% (between 12 and 26 weeks of follow-up), and incidence of serious adverse event …
Microneedling in androgenetic alopecia; comparing two different depths of microneedles.
Faghihi G, Nabavinejad S, Mokhtari F, Fatemi Naeini F, Iraji F. Faghihi G, et al. J Cosmet Dermatol. 2021 Apr;20(4):1241-1247. doi: 10.1111/jocd.13714. Epub 2020 Sep 29. J Cosmet Dermatol. 2021. PMID: 32897622
METHODS: Sixty patients, in the age of 18-45 years old with moderate and severe AGA, were allocated into 3 groups of control: treatment with minoxidil 5% lotion; group A: treatment with minoxidil 5% lotion and biweekly microneedling with a depth of 1.2 mm and group B: treatment w …
METHODS: Sixty patients, in the age of 18-45 years old with moderate and severe AGA, were allocated into 3 groups of control: treatment with …
A randomized, single-blinded, vehicle-controlled study of a topical active blend in the treatment of androgenetic alopecia.
Katoulis AC, Liakou AI, Koumaki D, Vakirlis E, Tsantes AG, Mortaki D, Bozi E, Ioannides D. Katoulis AC, et al. Dermatol Ther. 2020 Jul;33(4):e13734. doi: 10.1111/dth.13734. Epub 2020 Jul 13. Dermatol Ther. 2020. PMID: 32473084 Clinical Trial.
Forty-four patients with AGA were randomized either to apply the active lotion or the vehicle, twice daily for 24 weeks. Subjects were evaluated at 0, 12, and 24 weeks by clinical examination, photographic documentation, quality of life evaluation (DLQI), and trichogram (a …
Forty-four patients with AGA were randomized either to apply the active lotion or the vehicle, twice daily for 24 weeks. Subjects were evalu …
520 results